Drug Trial Radar · NCT07858422
A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Oct 8, 2026
Primary completion
Mar 15, 2027
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- Energenesis Biomedical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with epidermolysis bullosa simplex (EBS), junctional epidermolysis bullosa (JEB), or dystrophic epidermolysis bullosa (DEB). In total, approximately 24 subjects will be enrolled from multiple sites in Taiwan. The study duration per subject is approximately 16 weeks; which includes a 2 to 4-week period between Visit 1 and Visit 2 for screening, an 8-week period from Visit 2 to Visit 7 for treatment, and a 4-week period from Visit 7 to Visit 9 for safety follow-up.
Conditions
- Epidermolysis Bullosa (EB)
- Junctional Epidermolysis Bullosa
- Epidermolysis Bullosa Simplex
- Dystrophic Epidermolysis Bullosa
Interventions
ENERGI-F703EB CreamDrug
Standard of care and ENERGI-F703EB Cream is applied for the treatment of Epidermolysis Bullosa
Matched vehicle creamDrug
Standard of care and matched vehicle cream is applied for the treatment of Epidermolysis Bullosa
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Local Target Lesion Adverse EventsTime frame: Day 1 through Day 85
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.